Align Technology Authorizes $200 Million Share Buyback Program Align Technology Inc., a global leader in digital orthodontics and restorative dentistry, has announced plans to repurchase $200 million of its common stock through open market transactions. The move is part of…
Summit Therapeutics Announces Q1 2026 Financial Results and Highlights Key Operational Achievements Summit Therapeutics Inc. (NASDAQ: SMMT) has reported its financial results for the first quarter ended March 31, 2026, while also providing a comprehensive update on its clinical pipeline…
CareDx Reports Financial Results for First Quarter 2026 CareDx Inc., a leading precision medicine company dedicated to improving outcomes for transplant patients, has reported strong financial results for the first quarter ended March 31, 2026. The company’s performance reflects significant…
QIAGEN Announces Preliminary Q1 2026 Results, Meets Adjusted EPS Outlook Amid Mixed Sales Performance and Revises Full-Year 2026 Guidance QIAGEN N.V. has released its preliminary financial results for the first quarter of 2026, highlighting a period marked by strong profitability…
Correction and Replacement: Samsung Epis Holdings Announces First Quarter 2026 Financial Results Samsung Epis Holdings has released its financial results for the first quarter of fiscal year 2026, presenting a picture of steady growth supported by the continued expansion of…
Synthekine Showcases Updated Clinical and Translational Data Highlighting Strong STK-012 Activity in First-Line Non-Squamous NSCLC at AACR 2026 Synthekine, a clinical-stage biotechnology firm focused on engineering precision cytokine therapeutics, has reported updated clinical and translational findings for its investigational agent…
CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results CareDx, Inc.,The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated,…
Antiva Biosciences Presents Data from Phase 1b/2 Study of ABI-2280 for Treatment of Cervical High-Risk HPV Infection at SGO 2026 Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of high-risk infections and pre-cancerous lesions caused by…
Verastem Oncology Presents Two-Year Median Follow-Up Data for AVMAPKI®–FAKZYNJA® Combination in Recurrent Low-Grade Serous Ovarian Cancer at SGO 2026 Annual Meeting on Women’s Cancers Verastem Oncology (Nasdaq: VSTM), a company dedicated to developing innovative therapies for cancers driven by the…
ReAlta Life Sciences Completes Oversubscribed $40M Financing to Support Pegtarazimod Phase 2 Development in Hypoxic Ischemic Encephalopathy (HIE) ReAlta Life Sciences Inc. (“ReAlta”), a clinical-stage biopharmaceutical company focused on targeting neutrophil activity and key components of the complement system to…
GenSight Biologics Provides Update on Cash Position and Early Access Program Revenue as of March 31, 2026 GenSight Biologics, a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative gene therapies targeting retinal neurodegenerative diseases and central nervous…
Target RWE Enhances Leadership Team with Key Appointments Across Delivery, Finance, and Commercial Functions Target RWE, a company focused on advancing modern approaches to clinical evidence generation, has announced a series of strategic leadership updates aimed at supporting its next…